Table 2.
Clinical features of 18 cases of epithelioid inflammatory myofibroblastic sarcoma
| Author, Year | Case | Age/Sex | Site | Size (cm) | Treatment | Recurrence or metastasis | Follow-up Status (m) |
|---|---|---|---|---|---|---|---|
| Yu et al., 2016 | 1 | 37 y/F | Rectum | 5 | SE | No recurrence and metastasis | 8 (NED) |
| 2 | 55 y/M | Mesentery of ileum | 11 | SE, CT | Recurred at 2 m | 10 (NED) | |
| 3 | 22 y/M | Mesentery of colon | 20 | SE, ALKi | Recurred at 2 m | 14 (AWD) | |
| 4 | 58 y/F | Omentum | 5.5 | SE, CT | Recurred at 2 m | 8 (DOD) | |
| 5 | 15 y/F | Transverse colon | 10 | SE | No recurrence and metastasis | 7 (NED) | |
| Telugu et al., 2017 | 6 | 3 y/F | Suprarenel | 15 | SE, CT | Metastasis to liver and lung | 8 (DOD) |
| Jiang et al., 2017 | 7 | 45 y/M | Abdominal cavity | 20 | SE, CT | Metastasis to liver, spleen, small intestine et al. | 1 (DOD) |
| Lee et al., 2018 | 8 | 42 y/M | Abdominal cavity | NA | NA | Recurred at 8 m | 40 (AWD) |
| 9 | 34 y/M | Liver | NA | NA | Recurred at 5 m | 5 (DOD) | |
| 10 | 62 y/M | Abdominal cavity | NA | NA | NA | 2 (DOD) | |
| 11 | 76 y/F | Abdominal cavity | NA | NA | NA | 4 (DOD) | |
| 12 | 30 y/M | Abdominal cavity | NA | NA | NA | 8 (DOD) | |
| 13 | 26 y/M | Abdominal cavity | NA | NA | Recurred at 7&16 m | 16 (AWD) | |
| 14 | 39 y/M | Abdominal cavity | NA | NA | Recurred at 10 m | 10 (AWD) | |
| 15 | 7 m/M | Abdominal cavity | NA | NA | NA | 36 (DOD) | |
| 16 | 16 y/F | Lung | NA | NA | Recurred at 1 m | 48 (AWD) | |
| Du et al., 2018 | 17 | 26 y/M | Pelvic cavity | 5 | SE, CT | NA | 8 (DOD) |
| Hong et al., 2018 | 18 | 15 y/F | Ovary | NA | ALKi | Multiple recurrences | 24 (AWD) |
| Current case | 19 | 35 y/F | Stomach | NA | No | No | 11 (NED) |
NA not available, SE surgical excision, CT chemotherapy, ALKi ALK inhibitor, DOD died of disease, NED no evidence of disease, AWD alive with disease.